Mikkelsen, Nanna S.
Bak, Rasmus O. http://orcid.org/0000-0002-7383-0297
Funding for this research was provided by:
Sundhedsstyrelsen (4-1612-391/1)
HORIZON EUROPE European Research Council, ERC starting grant (101041231)
HORIZON EUROPE Research and Innovation Actions (101057438)
Lundbeckfonden (R238-2016-3349)
Danmarks Frie Forskningsfond (0134-00113B, 0242-00009B, 9144-00001B)
Aarhus Universitets Forskningsfond (609033)
Novo Nordisk Fonden (NNF19OC0058238, NNF17OC0028894)
Innovationsfonden (8056-00010B)
Carlsbergfondet (CF20-0424, CF17-0129)
Slagtermester Max Wørzner og Hustru Inger Wørzners Mindelegat
Den A. P. Møllerske Støttefond
Riisfort Fonden
Agnes og Poul Friis Fond
Genome Engineer Innovation Grant, Synthego
Article History
Received: 6 May 2023
Accepted: 26 June 2023
First Online: 1 July 2023
Declarations
:
: Not applicable.
: Not applicable.
: ROB holds equity in Graphite Bio and UNIKUM Tx and is part-time employee of UNIKUM Therapeutics. NSM declare no competing interests.